AKBA - Akebia GAAP EPS of -$0.09 misses by $0.01 revenue of $32.6M misses by $13.49M
2024-05-09 07:21:26 ET
More on Akebia
- Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
- Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
- Akebia Q1 2024 Earnings Preview
- Akebia stock jumps as FDA clears renal anemia therapy
- Seeking Alpha’s Quant Rating on Akebia